Dr. Jimmy Wang, director of the SEDDS Technology Institute, graduated from Polytechnic Institute of New York University in Ph.D. degree of medicinal chemistry, the famous Chinese-American scientist, the founder of American Health Formulations Co., Ltd., a former senior inspector of the FDA, CEO of MTC materials company.
Dr. Peter Gao is the senior fellow of Chinese Academy of Sciences in the early eighties, a former U.S. Pfizer Senior Fellow for twenty years, who has published dozens of papers. In the United States he is a part of more than 20 patents, is one of the top scientists in research on the soluble drugs. Now he is an R & D Director of SEDDS Technology Institute, American Health Formulations Co., Ltd.
Dr. John Cavallo graduated from the Massachusetts Institute of Technology, has many years of experience in the study of natural products and spices, he is the expert on flavors and fragrances. Now he is an R & D Director of SEDDS Technology Institute, American Health Formulations Co., Ltd.
Dr. Arati A Deshpande is an experienced, solution-driven formulator with more than 18 years of experience in research and development in the pharmaceutical industry. She earned her Ph.D in Pharmaceutical Sciences from University of Rhode Island, RI, USA. She was a post-doctoral fellow at University of Geneva, Geneva, Switzerland.
Arati has extensive knowledge of all aspects of the drug development process and is an expert in oral (solid and liquid) dosage forms as well as soft gels. She has developed and submitted many ANDAs to the US FDA and has successfully developed many formulations around PIV. Arati also has experience in other delivery routes such as transdermal, nasal, ophthalmic etc. She is a seasoned manager and a leader who excels in a high-stress, competitive environment, and a valuable addition to our team.
Qianwen "Sara" Gan, MS
Qianwen earned Master’s degree in Chemistry from State University of New York Stony Brook University, Stony Brook, NY, USA.
She did R&D research on Structure-activity relationships (SAR) study of α-truxillic acid-based fatty acid binding protein inhibitors as anti-nociceptive and anti-inflammatory drugs and Design and development of small molecule inhibitors of matrix metalloproteinase 9 in Prof. Iwao Ojima’s group.
Jinhui Dou, Ph.D.
After receiving his BS (Pharmacy) and MS (Pharmacognosy) degrees, Jinhui Dou became a faculty member at Beijing University of Chinese Medicine and taught pharmacy classes for 4 years.
He accepted a graduate assistantship from the Pharmacognosy Department at the University of Mississippi and received a PhD degree in 1996 from Dr. James McChesney, a distinguished professor of pharmacognosy. After working at the University of Kansas as a post-doc associate, he became a Natural Product Scientist at NaPro BioTherapeutics in December 1996. He led a group of chemists and engineers in the reduction of paclitaxel manufacturing costs and in the establishment of a library of related-substance reference standards to support the CMC, pharmacology, and toxicology sections of paclitaxel NDA and ANDA filings.
Dr. Dou joined the FDA in 2002 as a pharmacologist reviewer in the Center for Drug Evaluation and Research (CDER). He reviewed anti-infective and anti-inflammatory chemical-drug filings for several years before working as a botanical reviewer full time. He was a CDER and Agency expert pharmacologist and pharmacognosist specialized in botanical drug review. Dr. Dou received numerous awards from CDER, FDA, and HHS for his distinguished contributions to the development of new guidances, policies, and regulations and his scientific reviews of new botanical and chemical drugs.
After more than 15 years at FDA, Dr. Dou, in 2017, joined Yiling Pharmaceutical, headquartered in Shijiazhuang, China, as a Vice Dean of the Yiling Research Institute. He now works as a pharmacology and pharmacognosy consultant for the pharmaceutical industry worldwide.
Dr. Dou is a member of American Society of Pharmacognosy (ASP) and the NIH/NCI PDQ Integrative, Alternative, and Complementary Therapies (IACT) editorial board. His publications on lupin alkaloids, green tea, quassinoinds, and proanthocyanidins are from his research activities or new drug review experience.